Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | PHASE1 | RECRUITING | 165 | — | — | May 27, 2019 | Jan 1, 2028 | Jun 18, 2025 | 9 | China, China +7 |
| Name | Type | Description |
|---|---|---|
| APG-2449 | DRUG | Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle |